Cargando…

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men

BACKGROUND: The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and efficacy of the MRK Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine vs placebo in sexually active HIV-1 seronegative participants in South Africa. Enrollment and vaccinations stopped and participants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moodie, Zoe, Metch, Barbara, Bekker, Linda-Gail, Churchyard, Gavin, Nchabeleng, Maphoshane, Mlisana, Koleka, Laher, Fatima, Roux, Surita, Mngadi, Kathryn, Innes, Craig, Mathebula, Matsontso, Allen, Mary, Bentley, Carter, Gilbert, Peter B., Robertson, Michael, Kublin, James, Corey, Lawrence, Gray, Glenda E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569275/ https://www.ncbi.nlm.nih.gov/pubmed/26368824 http://dx.doi.org/10.1371/journal.pone.0137666

Ejemplares similares

Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women
por: Latka, Mary H., et al.
Publicado: (2012)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
por: Allen, MA, et al.
Publicado: (2009)

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial
por: de Bruyn, G, et al.
Publicado: (2009)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
por: Volk, JE, et al.
Publicado: (2012)

P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine
por: Latka, M, et al.
Publicado: (2009)

P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research
por: Mark, D, et al.
Publicado: (2009)

Oral and oropharyngeal high-risk HPV prevalence, HIV status, and risk behaviours in a cohort of South African men who have sex with men
por: Mistry, Harshita B, et al.
Publicado: (2021)

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa
por: Lazarus, Erica Maxine, et al.
Publicado: (2014)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Ditse, Zanele, et al.
Publicado: (2020)

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults
por: Gray, Glenda E, et al.
Publicado: (2021)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

Review of preventative HIV vaccine clinical trials in South Africa
por: Laher, Fatima, et al.
Publicado: (2020)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

The path to find an HIV vaccine
por: Gray, Glenda E, et al.
Publicado: (2021)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa
por: Mashingaidze, Rujeko, et al.
Publicado: (2023)

Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis
por: Lawal, Ismaheel O., et al.
Publicado: (2022)

Attracting, equipping and retaining young medical doctors in HIV vaccine science in South Africa
por: Flood, Danna, et al.
Publicado: (2015)

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
por: Malahleha, Mookho, et al.
Publicado: (2023)

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models
por: Dimitrov, Dobromir, et al.
Publicado: (2015)

HIV vaccines beyond COVID‐19: merits of trust
por: Kublin, James G
Publicado: (2021)

Hope for HIV control in southern Africa: The continued quest for a vaccine
por: Bekker, Linda-Gail, et al.
Publicado: (2017)

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
por: Palli, Rohith, et al.
Publicado: (2020)

Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline
por: Laher, Fatima, et al.
Publicado: (2023)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

“Why Don’t You Go Into Suburbs? Why Are You Targeting Us?”: Trust and Mistrust in HIV Vaccine Trials in South Africa
por: Thabethe, Siyabonga, et al.
Publicado: (2018)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

HIV vaccines: progress and promise
por: Johnston, Margaret I., et al.
Publicado: (2021)

Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa
por: Lazarus, Erica, et al.
Publicado: (2019)

“. . . I’ve Gone Through This My Own Self, So I Practice What I Preach . . . ”: Strategies to Enhance Understanding and Other Valued Outcomes in HIV Vaccine Trials in South Africa
por: Slack, Catherine, et al.
Publicado: (2016)

Competing biomedical HIV prevention strategies: potential cost‐effectiveness of HIV vaccines and PrEP in Seattle, WA
por: Adamson, Blythe, et al.
Publicado: (2019)

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination
por: Cram, Jacob A., et al.
Publicado: (2019)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7qoda9s6cjodfg96m3qir2vbib